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Abstract: The current study systematically reviewed, summarized and meta-analyzed the clinical
features of the vaccines in clinical trials to provide a better estimate of their efficacy, side effects and
immunogenicity. All relevant publications were systematically searched and collected from major
databases up to 12 March 2021. A total of 25 RCTs (123 datasets), 58,889 cases that received the
COVID-19 vaccine and 46,638 controls who received placebo were included in the meta-analysis. In
total, mRNA-based and adenovirus-vectored COVID-19 vaccines had 94.6% (95% CI 0.936–0.954)
and 80.2% (95% CI 0.56–0.93) efficacy in phase II/III RCTs, respectively. Efficacy of the adenovirus-
vectored vaccine after the first (97.6%; 95% CI 0.939–0.997) and second (98.2%; 95% CI 0.980–0.984)
doses was the highest against receptor-binding domain (RBD) antigen after 3 weeks of injections.
The mRNA-based vaccines had the highest level of side effects reported except for diarrhea and
arthralgia. Aluminum-adjuvanted vaccines had the lowest systemic and local side effects between
vaccines’ adjuvant or without adjuvant, except for injection site redness. The adenovirus-vectored
and mRNA-based vaccines for COVID-19 showed the highest efficacy after first and second doses,
respectively. The mRNA-based vaccines had higher side effects. Remarkably few experienced
extreme adverse effects and all stimulated robust immune responses.
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1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a non-segmented
positive-sense, single-stranded ribonucleic acid (RNA) beta coronavirus [1] that was first
reported in Wuhan, China. The SARS-CoV-2 infection causes the coronavirus disease 2019
(COVID-19) that became a global pandemic and public health crisis. Over 140 million
infected and 3 million deaths are reported from COVID-19 by April 2021, with the death
rate accelerating; according to WHO, the case fatality ratio (CFR) of SARS-CoV-2 ranges
from less than 0.1% to over 25% depending on the country [2].
To overcome this pandemic, vaccination is the hope for a safe and effective way to
help build protection and reduce disease spread [3]. More than 200 COVID-19 vaccine
candidates presented in different stages of development and over 50 candidates have
reached clinical trials to date [4], including: Oxford-AstraZeneca’s ChAdOx1/AZD1222,
Moderna’s mRNA-1273, Pfizer-BioNTech’s mRNA BNT162b2, Gamaleya’s Sputnik V,
Johnson & Johnson’s INJ-7843735/Ad26.COV2.s, CoronaVac, Sinopharm’s BBIBP-CorV,
Novavax’s NVX-CoV2373, EpiVacCorona, CanSino’s Convidicea (Ad5-nCoV), SinoVac’s
Vaccines 2021, 9, 467. https://doi.org/10.3390/vaccines9050467 https://www.mdpi.com/journal/vaccines
Vaccines 2021, 9, 467 2 of 21
CoronaVac, Anhui Zhifei Longcom’s ZF2001, GlaxoSmithKline and Medicago’s CoVLP,
and Bharat Biotech’s BBV152/Covaxin.
Different strategies have been considered for the development of vaccines against
SARS-CoV-2 based on the following vaccine platforms: (I) Nucleic acid mRNA-based
vaccines are the newest generation of vaccine production approach [5]. The mRNA vac-
cine technology is a single-stranded RNA molecule that carries a portion of the coding
sequence for the peptide or protein from the virus that can be synthesized in the cytoplasm
(ribosomes). The resulting antigen triggers an immune response, including the production
of antibodies [5]. For instance, the current vaccines developed by the companies Pfizer and
Moderna utilize synthetic mRNA encoding the sequence of the coronavirus’s signature
spike protein (S-protein) that is then encapsulated within a lipid vesicle nanoparticle. (II) Vi-
ral vector vaccines that are developed with new biotechnology [6]. A modified existing
virus, able to infect human cells, is introduced carrying the genetic code of the target virus
antigen in order to stimulate an immune response. Oxford-AstraZeneca, Gamaleya, CanSio
and Johnson & Johnson developed their vaccines based on a DNA sequence encoding the
S-protein inserted into the genome of a modified safe adenovirus. (III) Whole-Pathogen
Inactivated virus vaccines consisting of killed/inactivated whole viruses or virus fragments.
Here the pathogen’s genetic material is destroyed by heat, chemicals, or radiation, so that
they cannot replicate but their presence can still stimulate immunogenicity [7]. Sinopharm,
SinoVac, and Bharat Biotech’s vaccines were produced by inactivating the SARS-CoV-2
with B-propiolactone, but all the viral protein remains intact. (IV) Subunit vaccines that
contain a fragment of the pathogen, either a protein (Pro-subunit), a polysaccharide, or a
combination of both, without introducing viable pathogen particles [8]. Lack of genetic
material makes them safe and non-infectious/non-viable. Novavax and Anhui Zhifei
Longcom applied this technology for the development of their vaccine, using nanoparti-
cles coated with synthetic S-protein and an adjuvant for boosting the immune response.
Virus-like particle (VLP) vaccines, also a subunit vaccine, mimic the native virus structure,
but contain no viral genetic material [9]. A VLP presents the antigen inserted on a nanopar-
ticle surface. GlaxoSmithKline and Medicago used a plant-derived platform to produce
a particle that elicits neutralizing antibody and immune cell (e.g., TH1 T cell) responses
against COVID-19.
The structural proteins of SARS-CoV-2 include four major proteins: spike (S), mem-
brane (M), and envelope (E) part of the viral surface envelope, and the nucleocapsid (N)
protein in the ribonucleoprotien core. Among viral surface elements, the S-protein is a
primary target for vaccines and therapeutic development against COVID-19 due to its role
in the receptor recognition for cell entry and cell membrane fusion process. The trimeric
S-protein contains two subunits, S1 and S2. The S1 contains a receptor-binding domain
(RBD), which is responsible for recognizing and binding to the host receptor angiotensin-
converting enzyme 2 (ACE2), while the S2 mediates the membrane fusion process by
forming a six-helical bundle (6-HB) via the two-heptad repeat (HR) regions [10]. However,
S1 is the immunodominant antigen during CoV infections and induces long-lasting and
broad-spectrum neutralizing antibodies (NAbs) and T-cell immune responses against the
RBD. Thus, the S-protein and the RBD serve as the promising targets of SARS-CoV-2 vac-
cines and the predominant antigenic target for developing a vaccine [11]. Other antigenic
targets, such as non-structural proteins (nsp) 3, nsp8-10 [12], papain-like proteases (PL-
pro), and cysteine-like protease (3CLpro) [13] can be considered an alternative for vaccine
development, but these are expected to elicit less of an immune response.
Efficacy and safety, thus side effect profiles, are core vaccine competencies required by
medical care systems and public health. To the best of our knowledge, there is still no com-
prehensive comparative study around the efficacy and safety of COVID-19-related vaccines.
In this regard, we provide here a meta-analysis on available randomized clinical trial (RCT)
publications providing information on the efficacy and side effects of COVID-19 vaccines.
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2. Methods
2.1. Search Strategy
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses State-
ment (PRISMA) recommendations were followed in this analysis [14]. We searched all
clinical trial publications related to SARS-CoV-2 vaccines from the following databases:
Scopus, EMBASE, Medline (via PubMed), and Web of Science. All studies published
up to 12 March 2021 were searched without language restriction by three independent
reviewers. Search medical subject headings (MeSH) terms used were “Covid-19 Vaccine”,
“SARS-CoV-2 Vaccine”, “clinical trial” or “phase trial”, and “randomized”, as well as all
synonyms. We used the Center for Disease Control (CDC), World Health Organization
(WHO), and Google Scholar databases/academic search engines to look for unpublished
and grey literature. References and citation lists of selected articles and reviews were also
reviewed for any other relevant literature (forward and backward citation, recommended
by Cochrane). Additional search strategy details are provided in Table S1.
2.2. Study Selection
The records were first reviewed by three independent authors based on the title and
abstract (MHR, AP, and SG), all unrelated publications were removed and the full texts
of the remaining articles were reviewed. Then, two independent reviewers (AP and SG)
judged potentially eligible articles and disagreements were resolved by discussion and for
each article a consensus was reached.
2.3. Eligibility and Inclusion Criteria
The following predetermined conditions had to be met for studies to be considered
for inclusion in this meta-analysis. For initial screening, all clinical studies were included
in the systematic review, while RCT studies in phase I/II/III of COVID-19 vaccines were
included in the meta-analysis.
2.4. Exclusion Criteria
Non-randomized studies, studies without a placebo group, preclinical studies, studies
on animal phase, meta-analyses, letters to the editor, review articles, studies with no
extractable data, and news reports were excluded for the meta-analysis. However, non-
randomized studies were included only in the systematic review. Additionally, 11 vaccine
studies (43 datasets) with no report in the type of adjuvants were excluded from the
adjuvant side effect sub-group meta-analysis.
2.5. Data Extraction
Four independent reviewers extracted data from the studies that were chosen. The
following data were obtained from each article: first authors, trial initiation date, published
year, vaccine name, company, study type, vaccine type, adjuvant, store temperature, trial
phase, doses, injection interval (days), concentration, volume, trial country, all side effects,
and efficacy-related data. Three of the authors (S.G, M.H.R, and A.P) extracted data
independently, and another author (M.Z) reviewed extracted data at random; discrepancies
were resolved by consensus.
2.6. Quality Assessment
The JADAD scale (Oxford quality scoring system) for reporting quality of RCTs was
used to evaluate the included articles’ quality. The JADAD scale included the three quality
parameters of randomization, blinding, and account of all patients. Two questions are
asked for the first two parameters, and one question is asked for the third parameter. Each
query is given a score of one or zero. The highest acceptable score on the prepared checklist
was five, with the lowest acceptable score being three. Data were derived from papers with
a ranking of at least three (Table S2).
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2.7. Analysis
Initially, cleaning data and preparing them for analysis was done in Microsoft Office
365 and analysis was performed by Comprehensive Meta-Analysis Software Version 2.0
software. The point estimates of the effect size, odds ratios (ORs), and 95% confidence
interval (95% CI) were calculated for estimating vaccine efficacy and side effects. Random
effects models were used to estimate pooled effects. Additionally, to search for heterogene-
ity between studies, the I2 statistic was used [15] and high heterogeneity was characterized
as an I2 > 50%, with sources of heterogeneity established through meta-regression and
subgroup analyses. Subgroup analysis based on the vaccine phases significantly decreased
the heterogeneity in the high heterogeneity cases. The presence and effect of publication
bias were examined using funnel plots, Begg’s test, and Egger weighted regression meth-
ods [16,17]. For all analyses, two-tailed statistics and a significance level of less than 0.05
were considered.
3. Result
3.1. Characteristics of Included Studies
A total of 32,790 publications were screened for the COVID-19 vaccines’ side effects
and efficacies. Out of these studies, 27 met the systematic review’s inclusion criteria
(non-randomized and randomized), while 25 randomized studies were included in the
meta-analysis (Figure 1). Characteristics of the selected articles are summarized in Table 1.
A total of 25 studies (123 datasets) were included in the meta-analysis. Studies with different
vaccine phase reports, number of doses, injection concentration, different case, and control
group numbers are considered a separate dataset for the meta-analysis. All included
studies were written in English. Out of 25 randomized studies, 12 were double-blind,
2 participant-blind, 6 observer-blind, 3 single-blind, and 2 partially blind. The number
of studies by vaccine platforms were 7 mRNA-based, 4 pro-subunit, 8 adenovirus-vector,
5 inactivated, and 1 VLPs.
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Table 1. Characterization of included studies.










Interval (Days) Concentration Trial Country Ref
Yang et al. 22 June and 3 July 2020 2020 ZF2001 Anhui ZhifeiLongcom Randomized, double-blind, placebo-controlled Pro-Subunit
Aluminum
hydroxide 2–8 I 3 22.9–54.7 30 25 µg * China [18]
Yang et al. 22 June and 3 July 2020 2020 ZF2001 Anhui ZhifeiLongcom Randomized, double-blind, placebo-controlled Pro-Subunit
Aluminum
hydroxide 2–8 I 3 20.9–49.4 30 50 µg * China [18]
Ella et al. 13 and 30 July 2020 2021 BBV152(Covaxin) Bharat Biotech Randomized, double-blind, placebo-controlled Inactivated Algel-IMDG 2–8 I 2 18–55 14 3 µg * India [19]
Ella et al. 13 and 30 July 2020 2021 BBV152(Covaxin) Bharat Biotech Randomized, double-blind, placebo-controlled Inactivated Algel-IMDG 2–8 I 2 18–55 14 6 µg * India [19]
Ella et al. 13 and 30 July 2020 2021 BBV152(Covaxin) Bharat Biotech Randomized, double-blind, placebo-controlled Inactivated Algel 2–8 I 2 18–55 14 6 µg* India [19]
Zhu et al. 16 and 27 March 2020 2020 Ad5-nCoV CanSino Non-randomized Adenovirus-based No adjuvant UN I 1 18–60 No 5 × 10
10 VP * China [20]
Zhu et al. 16 and 27 March 2020 2020 Ad5-nCoV CanSino Non-randomized Adenovirus-based No adjuvant UN I 1 18–60 No 1 × 10
11 VP * China [20]
Zhu et al. 16 and 27 March 2020 2020 Ad5-nCoV CanSino Non-randomized Adenovirus-based No adjuvant UN I 1 18–60 No 1.5 × 10
11 VP * China [20]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit No adjuvant 2–8 I 2 20–50 21 3 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit AS03 2–8 I 2 24–53 21 3 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit AS03 2–8 I 2 55–70 21 3 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit CpG/Alum 2–8 I 2 20–53 21 3 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit CpG/Alum 2–8 I 2 55–71 21 3 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit No adjuvant 2–8 I 2 20–54 21 9 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit AS03 2–8 I 2 21–53 21 9 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit AS03 2–8 I 2 55–64 21 9 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit CpG/Alum 2–8 I 2 19–55 21 9 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit CpG/Alum 2–8 I 2 55–67 21 9 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit No adjuvant 2–8 I 2 18–49 21 30 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit AS03 2–8 I 2 19–47 21 30 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit AS03 2–8 I 2 55–63 21 30 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit CpG/Alum 2–8 I 2 21–50 21 30 µg * Australia [21]
Richmond et al. 19 June and 23 September 2020 2021 SCB-2019 Clover Randomized, double-blind, placebo-controlled Pro-Subunit CpG/Alum 2–8 I 2 55–74 21 30 µg * Australia [21]
Kremsner et al. June, 2020 2020 CVnCoV Curevac Randomized, partially blind, placebo-controlled mRNA-based No adjuvant 5 I 2 18–60 28 2 µg * Germany [22]
Kremsner et al. June, 2020 2020 CVnCoV Curevac Randomized, partially blind, placebo-controlled mRNA-based No adjuvant 5 I 2 19–59 28 4 µg * Germany [22]
Kremsner et al. June, 2020 2020 CVnCoV Curevac Randomized, partially blind, placebo-controlled mRNA-based No adjuvant 5 I 2 20–59 28 6 µg * Germany [22]
Kremsner et al. June, 2020 2020 CVnCoV Curevac Randomized, partially blind, placebo-controlled mRNA-based No adjuvant 5 I 2 20–59 28 8 µg * Germany [22]
Kremsner et al. June, 2020 2020 CVnCoV Curevac Randomized, partially blind, placebo-controlled mRNA-based No adjuvant 5 I 2 19–59 28 12 µg * Germany [22]
Ward et al. July, 2020 2020 CoVLP Medicago Randomized, partially blind VLP No adjuvant 2–8 I 2 18–55 21 3.75 µg * Canada [23]
Ward et al. July, 2020 2020 CoVLP Medicago Randomized, partially blind VLP CpG 1018 2–8 I 2 18–55 21 3.75 µg * Canada [23]
Ward et al. July, 2020 2020 CoVLP Medicago Randomized, partially blind VLP AS03 2–8 I 2 18–55 21 3.75 µg * Canada [23]
Ward et al. July, 2020 2020 CoVLP Medicago Randomized, partially blind VLP No adjuvant 2–8 I 2 18–55 21 7.5 µg * Canada [23]
Ward et al. July, 2020 2020 CoVLP Medicago Randomized, partially blind VLP CpG 1018 2–8 I 2 18–55 21 7.5 µg * Canada [23]
Ward et al. July, 2020 2020 CoVLP Medicago Randomized, partially blind VLP AS03 2–8 I 2 18–55 21 7.5 µg * Canada [23]
Ward et al. July, 2020 2020 CoVLP Medicago Randomized, partially blind VLP No adjuvant 2–8 I 2 18–55 21 15 µg * Canada [23]
Ward et al. July, 2020 2020 CoVLP Medicago Randomized, partially blind VLP CpG 1018 2–8 I 2 18–55 21 15 µg * Canada [23]
Ward et al. July, 2020 2020 CoVLP Medicago Randomized, partially blind VLP AS03 2–8 I 2 18–55 21 15 µg Canada [23]
Jackson et al. 16 March and 14 April 2020 2020 mRNA-1273 Moderna Open-label mRNA-based No adjuvant −20 I 2 18–55 28 25 µg * United States [24]
Jackson et al. 16 March and 14 April 2020 2020 mRNA-1273 Moderna Open-label mRNA-based No adjuvant −20 I 2 18–55 28 100 mg * United States [24]
Jackson et al. 16 March and 14 April 2020 2020 mRNA-1273 Moderna Open-label mRNA-based No adjuvant −20 I 2 18–55 28 250 mg * United States [24]
Anderson et al. 16 April and 12 May 2020 2020 mRNA-1273 Moderna Open-label mRNA-based No adjuvant −20 I 2 56–70 28 25 mg * United States [25]
Anderson et al. 16 April and 12 May 2020 2020 mRNA-1273 Moderna Open-label mRNA-based No adjuvant −20 I 2 71≤ 28 25 mg * United States [25]
Anderson et al. 16 April and 12 May 2020 2020 mRNA-1273 Moderna Open-label mRNA-based No adjuvant −20 I 2 56–70 28 100 mg * United States [25]
Anderson et al. 16 April and 12 May 2020 2020 mRNA-1273 Moderna Open-label mRNA-based No adjuvant −20 I 2 71≤ 28 100 mg * United States [25]
Keech et al. 26 May and 6 June 2020 2020 NVX-CoV2373 Novavax Randomized, observer-blind, placebo-controlled Pro-Subunit No adjuvant 2–8 I 2 18–59 21 25 µg/0.6 ml Australia,United States [26]
Keech et al. 26 May and 6 June 2020 2020 NVX-CoV2373 Novavax Randomized, observer-blind, placebo-controlled Pro-Subunit Matrix-M1 2–8 I 2 18–59 21 5 µg/0.6 ml Australia,United States [26]
Keech et al. 26 May and 6 June 2020 2020 NVX-CoV2373 Novavax Randomized, observer-blind, placebo-controlled Pro-Subunit Matrix-M1 2–8 I 2 18–59 21 25 µg/0.6 ml Australia,United States [26]
Keech et al. 26 May and 6 June 2020 2020 NVX-CoV2373 Novavax Randomized, observer-blind, placebo-controlled Pro-Subunit Matrix-M1 2–8 I 1 18–59 21 25 µg/0.6 ml Australia,United States [26]
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Sahin et al. 23 April and 22 May 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, single-blind mRNA-based No adjuvant (−60)–(−80) I 2 18–55 21 1 µg * Germany [27]
Sahin et al. 23 April and 22 May 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, single-blind mRNA-based No adjuvant (−60)–(−80) I 2 21.4–55.8 21 10 µg * Germany [27]
Sahin et al. 23 April and 22 May 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, single-blind mRNA-based No adjuvant (−60)–(−80) I 2 25.1–55 21 30 µg * Germany [27]
Sahin et al. 23 April and 22 May 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, single-blind mRNA-based No adjuvant (−60)–(−80) I 2 23.9–54 21 50 µg * Germany [27]
Sahin et al. 23 April and 22 May 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, single-blind mRNA-based No adjuvant (−60)–(−80) I 1 19.9–47.8 No 60 µg * Germany [27]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 20.9–53.2 21 10 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 18–55 21 10 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 65–85 21 20 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 18–55 21 20 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 65–85 21 30 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) 1 2 18–55 21 30 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b2 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 65–85 21 10 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b2 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 18–55 21 10 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b2 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 65–85 21 20 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b2 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 18–55 21 20 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b2 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 65–85 21 30 µg * United States,Germany [28]
Walsh et al. 4 May and 22 June 2020 2020 BNT162b2 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I 2 18–55 21 30 µg * United States,Germany [28]
Xia et al. 12 April and 2 May 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 3 65–85 28 2.5 µg * China [29]
Xia et al. 12 April and 2 May 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 3 18–59 28 5 µg * China [29]
Xia et al. 12 April and 2 May 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 3 18–59 28 10 µg * China [29]
Xia et al. 29 April and 28 June 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 2 18–59 28 2 µg * China [30]
Xia et al. 29 April and 28 June 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 2 18–59 28 2 µg * China [30]
Xia et al. 29 April and 28 June 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 2 60 ≤ 28 4 µg * China [30]
Xia et al. 29 April and 28 June 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 2 18–59 28 4 µg * China [30]
Xia et al. 29 April and 28 June 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 2 60 ≤ 28 8 µg * China [30]
Xia et al. 29 April and 28 June 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 2 18–59 28 8 µg * China [30]
Zhang et al. 16 and 25 April 2020 2020 CoronaVac Sinovac Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 2 60≤ 14 3 µg * China [31]
Zhang et al. 16 and 25 April 2020 2020 CoronaVac Sinovac Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 2 18–59 28 3 µg * China [31]
Zhang et al. 16 and 25 April 2020 2020 CoronaVac Sinovac Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 2 18–59 14 6 µg * China [31]
Zhang et al. 16 and 25 April 2020 2020 CoronaVac Sinovac Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 I 2 18–59 28 6 µg * China [31]
Logunov et al. 18 June and 3 August 2020 2020 Sputnik V Gamaleya Non-randomized Adenovirus-based No adjuvant 2–8 I 1 18–59 No 10
11 VP * Russia [32]
Logunov et al. 18 June and 3 August 2020 2020 Sputnik V Gamaleya Non-randomized Adenovirus-based No adjuvant 2–8 I 1 18–60 No 10
11 * Russia [32]
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Logunov et al. 18 June and 3 August 2020 2020 Sputnik V (Lyo) Gamaleya Non-randomized Adenovirus-based No adjuvant 2–8 I 1 18–60 No 10
11 * Russia [32]
Logunov et al. 18 June and 3 August 2020 2020 Sputnik V (Lyo) Gamaleya Non-randomized Adenovirus-based No adjuvant 2–8 I 1 18–60 No 10
11 * Russia [32]
Folegatti et al. 23 April and 21 May 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-




Mulligan et al. 4 May and 19 June 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I/II 2 18–55 21 10 µg * Multicenter 1 [34]
Mulligan et al. 4 May and 19 June,2020 2020 BNT162b1 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I/II 2 24–42 21 30 µg * Multicenter 1 [34]
Mulligan et al. 4 May and 19 June 2020 2020 BNT162b1 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) I/II 1 23–52 No 100 µg * Multicenter 1 [34]
Yang et al. 12 and 17 July 2020 2020 ZF2001 Anhui ZhifeiLongcom Randomized, double-blind, placebo-controlled Pro-Subunit
Aluminum
hydroxide 2–8 II 2 25–53 30 25 µg * China [18]
Yang et al. 12 and 17 July 2021 2020 ZF2001 Anhui ZhifeiLongcom Randomized, double-blind, placebo-controlled Pro-Subunit
Aluminum
hydroxide 2–8 II 2 18.8–58.4 30 50 µg * China [18]
Yang et al. 12 and 17 July 2022 2020 ZF2001 Anhui ZhifeiLongcom Randomized, double-blind, placebo-controlled Pro-Subunit
Aluminum
hydroxide 2–8 II 3 19.9–59.1 30 25 µg * China [18]
Yang et al. 12 and 17 July 2023 2020 ZF2001 Anhui ZhifeiLongcom Randomized, double-blind, placebo-controlled Pro-Subunit
Aluminum
hydroxide 2–8 II 3 20–59.7 30 50 µg * China [18]
Zhu et al. 11 and 16 April 2020 2020 Ad5-nCoV CanSino Randomized, double-blind, placebo-controlled Adenovirus-based No adjuvant UN II 1 19.3–59.6 No 1 × 10
11 * China [35]
Zhu et al. 11 and 16 April 2020 2020 Ad5-nCoV CanSino Randomized, double-blind, placebo-controlled Adenovirus-based No adjuvant UN II 1 18≤ No 5 × 10
10 * China [35]
Chu et al. 29 May and 8 July 2020 2020 mRNA-1273 Moderna Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant −20 II 2 18≤ 28 50 mg * United States [36]
Chu et al. 29 May and 8 July 2020 2020 mRNA-1273 Moderna Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant −20 II 2 18–54.99 28 50 mg * United States [36]
Chu et al. 29 May and 8 July 2020 2020 mRNA-1273 Moderna Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant −20 II 2 55≤ 28 100 mg * United States [36]
Chu et al. 29 May and 8 July 2020 2020 mRNA-1273 Moderna Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant −20 II 2 18–54.99 28 100 mg * United States [36]
Ramasamy et al. 30 May and 8 August 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-




Ramasamy et al. 30 May and 8 August 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-




Ramasamy et al. 30 May and 8 August 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-




Ramasamy et al. 30 May and 8 August 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-




Ramasamy et al. 30 May and 8 August 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-




Ramasamy et al. 30 May and 8 August 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-





Ramasamy et al. 30 May and 8 August 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-





Ramasamy et al. 30 May and 8 August 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-





Ramasamy et al. 30 May and 8 August 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-





Ramasamy et al. 30 May and 8 August 2020 2020 AZD1222 Oxford/AstraZeneca Randomized, participant-blind,placebo-controlled
Adenovirus-





Xia et al. 12 April and 2 May 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 II 3 70≤ 28 5 µg * China [29]
Xia et al. 12 April and 2 May 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 II 3 18–59 28 5 µg * China [29]
Xia et al. 18 May and 30 July 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 II 1 18–59 No 8 µg * China [30]
Xia et al. 18 May and 30 July 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 II 2 18–59 14 4 µg * China [30]
Xia et al. 18 May and 30 July 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 II 2 18–59 21 4 µg * China [30]
Xia et al. 18 May and 30 July 2020 2020 BBIBP-CorV Sinopharm Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 II 2 18–59 28 4 µg * China [30]
Zhang et al. 3 and 5 May 2020 2020 CoronaVac Sinovac Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 II 2 18–59 14 3 µg * China [31]
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Zhang et al. 3 and 5 May 2020 2020 CoronaVac Sinovac Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 II 2 18–59 28 3 µg * China [31]
Zhang et al. 3 and 5 May 2020 2020 CoronaVac Sinovac Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 II 2 18–59 14 6 µg * China [31]
Zhang et al. 3 and 5 May 2020 2020 CoronaVac Sinovac Randomized, double-blind, placebo controlled Inactivated Aluminumhydroxide 2–8 II 2 18–59 28 6 µg * China [31]
Logunov et al. 18 June and 3 August 2020 2020 Sputnik V Gamaleya Non-randomized Adenovirus-based No adjuvant 2–8 II 2 18–59 21 10
11 VP * Russia [32]
Logunov et al. 18 June and 3 August 2020 2020 Sputnik V(lyophilised) Gamaleya Non-randomized
Adenovirus-
based No adjuvant 2–8 II 2 18–60 21 10
11 VP * Russia [32]
Voysey et al. 23 April and 4 November 2020 2021 AZD1222 Oxford/AstraZeneca Randomized, single-blind, placebo-controlled Adenovirus-based No adjuvant 2–8 II/III 2 18–60 28









Pollack et al. 27 July and 14 November 2020 2020 BNT162b2 Pfizer/BioNTech Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant (−60)–(−80) II/III 2 18≤ 21 30 µg/0.3 ml Multinational 1 [39]
Baden et al. 27 July and 23 October 2020 mRNA-1273 Moderna Randomized, observer-blind, placebo-controlled mRNA-based No adjuvant −20 III 2 16–89 28 100 µg * United States [40]
Voysey et al. 23 April and 4 November 2020 2021 AZD1222 Oxford/AstraZeneca Randomized, single-blind, placebo-controlled Adenovirus-based No adjuvant 2–8 III 2 18–95 28 5 × 10
10 VP * Brazil [38]
Logunov et al. 7 September and 24November 2020 2021 Sputnik V Gamaleya Randomized, double-blind, placebo controlled
Adenovirus-
based No adjuvant 2–8 III 2 18≤ 21 10
11 VP * Russia [41]
Sadoff et al. 20 July 2020 2021 Ad26.COV2.S Johnson &Johnson Randomized, double-blind, placebo-controlled
Adenoviral
vector No adjuvant UN I/II 2 18–55 No 5 × 10
10 Belgium, US [42]
Sadoff et al. 20 July 2020 2021 Ad26.COV2.S Johnson &Johnson Randomized, double-blind, placebo-controlled
Adenoviral
vector No adjuvant UN I/II 2 19–55 No 1 × 10
11 Belgium, US [42]
Sadoff et al. November 2020 2021 Ad26.COV2.S Johnson &Johnson Randomized, double-blind, placebo-controlled
Adenoviral
vector No adjuvant UN I/II 2 65–83 No 5 × 10
10 Belgium, US [42]
Sadoff et al. November 2020 2021 Ad26.COV2.S Johnson &Johnson Randomized, double-blind, placebo-controlled
Adenoviral
vector No adjuvant UN I/II 2 65–88 No 1 × 10
11 Belgium, US [42]
1 From 152 sites worldwide (United States, 130 sites; Argentina, 1; Brazil, 2; South Africa, 4; Germany, 6; and Turkey, 9). UN = unavailable. VP = virus particle; Pro-Subunit = protein subunit; VLP = virus-like
particle; Alum = aluminium; Adv= adenovirus; CpG = cytosine-guanine oligodeoxynucleotide; AS03= squalene-based immunologic adjuvant; Algel-IMDG (an imidazoquinoline molecule chemisorbed on alum
[Algel]); RCT = randomized control trial. * per 0.5 m. Studies with different reports for the vaccine phase, the vaccine dose, injection concentration, different case, and control group numbers are considered as a
separate dataset. More detailed information is provided in Table S3.
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3.2. Characteristics of Participants
A total of 58,889 cases that received the COVID-19 vaccine and 46,638 controls who
received placebo were included in this study. Out of 58,889 vaccine cases, 31,070 were male
and 27,819 female. Out of 46,638 individuals in the placebo group, 33,354 were male and
13,284 female. All vaccines and placebos were intramuscularly (IM) injected. Detailed
information of age ranges of either vaccine or placebo groups is shown in Table 1.
3.3. Efficacy of Different COVID-19 Vaccines
3.3.1. Efficacy of mRNA-Based COVID-19 Vaccines
The mRNA-based COVID-19 vaccines had 94.6% (95% CI 0.936–0.954) efficacy in a
total of 34,041 cases in phase II/III RCTs (Table 2). Figure 2 shows the efficacy of COVID-19
vaccines after the first and second doses. Efficacy four weeks after first dose was reported
for only one antibody (NAb 70.2% (95% CI 0.655–0.746)). Efficacy after a second dose of
mRNA-based COVID-19 vaccines was reported for RBD, S-protein, and NAbs, with the
highest efficacy for NAbs at 99.5% (95% CI 0.980–0.999) (Table 3).
Table 2. Efficacy of adenovirus-based and mRNA-based COVID-19 vaccines.
Vaccine Type RCT Phase
Number
Studies Efficacy (%)
95% CI (%) Included
Case N
Heterogeneity
Test, p-ValueLower Limit Upper Limit
Adenovirus-based 2/3 4 80.2 0.564 0.927 20771 <0.001
mRNA-based 2/3 2 94.6 0.936 0.954 34041 <0.001
RCT = randomized control trial.
3.3.2. Efficacy of Adenovirus-Vectored COVID-19 Vaccines
The pooling of four RCTs (in phases II/III) results (a total of 20,771 cases included)
showed adenovirus-vectored COVID-19 vaccines had 80.2% (95% CI 0.56–0.93) efficacy
(Table 2). After the first dose, the efficacy of the adenovirus-vectored COVID-19 vaccine
was the highest at 97.6% (95% CI 0.939–0.997) against RBD three weeks after injection.
Whereas, adenovirus-vectored COVID-19 vaccine had the highest efficacy by producing
NAbs 99.9% (95% CI 0.985–1.000) after 4 and 2 weeks of the second injection (Table 3).
3.3.3. Efficacy of Inactivated COVID-19 Vaccines
After the first vaccine dose, the inactivated COVID-19 vaccine’s efficacy was the
highest against RBD at 91.3% (95% CI 00.564–0.96) four weeks after injection. Whereas, the
highest efficacy against S-protein was 94% (95% CI 0.941 0.877–0.973) two weeks after the
second injection (Table 3).
3.3.4. Efficacy of Pro-Subunit COVID-19 Vaccines
Pro-subunit vaccine efficacy was the highest against RBD at 87.3% (95% CI 0.671–0.892)
four weeks after the first dose. Similarly, it had the highest efficacy against RBD protein at
95.6% (95% CI 0.937–0.970) four weeks after the second dose (Table 3).
3.3.5. Efficacy of VLP COVID-19 Vaccines
Efficacy of VLP vaccines was reported only against RBD three weeks after the first
dose at 23.8% (95% CI 0.091–0.375) and three weeks after the second dose at 78.7% (95% CI
0.581–0.908) (Table 3).
3.4. Side Effects of Different COVID-19 Vaccines
Adjusted pooled odds ratio (OR) between vaccine and placebo groups were assessed
for estimating the association of side effects by the administration of different COVID-19
vaccines. mRNA-based vaccines had the highest number of associated side effects, except
for diarrhea and arthralgia, for which the adenovirus-vectored vaccine had the highest OR
(Figure 3).
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Figure 2. Efficacy of different COVID-19 vaccines (a) after the first and (b) second doses.
The administration of mRNA-based vaccine was associated with a greater number
of side effects, such as injection site pain, fever, redness, swelling, induration, pruritus,
chills, myalgia, arthralgia, vomiting, fatigue, and headache, by yielding a summary OR
of 83.06 (95% CI 37.05–186.1) (in phase II/III RCTs), 36.90 (95% CI 12.34–105.21) (in phase
I/II/III RCTs), 24.40 (95% CI 18.73–31.77) (in phase I/II/III RCTs), 18.79 (95% CI 4.87–72.40)
(in phase I/II/III RCTs), 17.5 (95% CI 1.96–155.58) (in phase I/II RCTs), 17.50 (95% CI
1.98–155.58) (in phase II/III RCTs), 13.11 (95% CI 7.19–23.89) (in phase II/III RCTs), 10.71
(95% CI 6.51–17.60) (in phase I/II RCTs), 9.67 (95% CI 1.27–76.90) (in phase III/II RCTs),
8.71 (95% CI 4.38–17.34) (in phase I/II RCTs), 6.16 (95% CI 5.86–6.48) (in phase III RCTs),
and 5.13 (95% CI 2.32–11.31) (in phase I/II RCTs), respectively, compared to other types
of vaccines. Nevertheless, the adenovirus-vectored vaccine was associated with higher
rates of diarrhea with OR of .59 (95% CI 3.58–5.89), and arthralgia OR of 10.61 (95% CI
7.60–14.83) compared to others (Table 4). It should be considered that heterogeneity (I-
squared test) of the pooled meta-analysis for most of the side effects was low (I2 < 50%),
which indicates that variation in study outcomes between the included studies was low,
even though different companies and different research groups across the world have
been included. More detailed information such as Forest plot, Funnel plot, heterogeneity
test, and ub-group analysis of each side effects are shown in Figures S1–S21 (in the
Supplementary Materials).
Vaccines 2021, 9, 467 11 of 21








Adenovirus-based 4 0.603 0.471 0.722 73.8 2 0.004 0.001 0.027 0
Inactivated 4 0.870 0.734 0.983 93.8 4 0.024 0.008 0.072 0
3
Adenovirus-based 2 0.976 0.939 0.997 0.0 NA NA NA NA NA
VLP 8 0.238 0.091 0.375 84.3 NA NA NA NA NA
4
Adenovirus-based 2 0.966 0.942 0.980 0.0 2 0.004 0.001 0.027 0
Inactivated 4 0.913 0.564 0.958 90.7 4 0.061 0.033 0.110 0
Pro-Subunit 6 0.628 0.590 0.665 0.0 NA NA NA NA NA
S-protein
2 Inactivated 2 0.293 0.182 0.437 0.0 2 0.083 0.032 0.202 0
3 Pro-Subunit 4 0.790 0.474 0.874 91.0 4 0.021 0.005 0.079 0
4
Inactivated 2 0.396 0.269 0.539 0.0 2 0.021 0.003 0.134 0
Pro-Subunit 4 0.873 0.671 0.892 91.9 4 0.021 0.005 0.079 0
NAb
2 Inactivated 4 0.583 0.210 0.868 95.0 4 0.030 0.013 0.070 0
3 Pro-Subunit 4 0.551 0.291 0.786 85.0 4 0.021 0.005 0.079 0
4
Adenovirus-based 2 0.547 0.496 0.596 76.8 2 0.008 0.002 0.031 0
Inactivated 4 0.691 0.537 0.812 95.0 4 0.025 0.008 0.074 0




Inactivated 9 0.929 0.876 0.960 61.8 9 0.171 0.077 0.336 85
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3
Adenovirus-based 3 0.982 0.980 0.984 0.0 1 0.149 0.139 0.159 0
VLP 9 0.787 0.581 0.908 78.1 NA NA NA NA NA
4
Inactivated 4 0.944 0.842 0.982 15.9 4 0.063 0.026 0.143 0
Pro-Subunit 6 0.956 0.937 0.970 0.0 NA NA NA NA NA
S-protein
2
Inactivated 7 0.941 0.877 0.973 61.4 7 0.290 0.139 0.507 87
Pro-Subunit 18 0.852 0.719 0.928 62.4 18 0.028 0.014 0.052 0
mRNA-based 5 0.786 0.725 0.836 0.0 NA NA NA NA NA
4
Inactivated 4 0.934 0.842 0.974 15.9 4 0.063 0.026 0.143 0
Pro-Subunit 14 0.792 0.679 0.873 50.7 15 0.031 0.015 0.061 0
NAbs
2
Adenovirus-based 1 0.999 0.985 1.000 0.0 NA NA NA NA NA
Inactivated 9 0.845 0.724 0.919 86.5 9 0.151 0.068 0.303 85
Pro-Subunit 23 0.753 0.667 0.823 68.2 19 0.028 0.015 0.052 0
mRNA-based 9 0.870 0.747 0.938 82.4 4 0.008 0.003 0.024 0
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4
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S-protein = spike protein, Alum = aluminium, CpG = cytosine-guanine oligodeoxynucleotide, AS03 = squalene-based immunologic adjuvant, RBD = receptor-binding domain, NAb = neutralizing antibody,
Pro-Subunit = protein subunit, NA = not available.
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2/3 83.06 (37.05–186.1) 5 81.33
1/2 28.26 (16.18–49.35) 17 0
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Pro-Subunit 1/2/3 6.48 (3.09–13.67) 5 0
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Adenovirus-based 1/2/3 1.35 (0.815–2.25) 4 0
Pro-Subunit 1/2/3 7.29 (3.70–14.38) 6 0
mRNA-based 1/2/3 24.40 (18.73–31.77) 1 0
Itch
Adenovirus-based 1/2 3.10 (1.96–4.89) 1 0
Inactivated 1/2 0.32 (0.02–5.3) 1 0
Pro-Subunit 1/2 25.44 (7.85–82.40) 6 0
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Table 4. Cont.
Side Effect Vaccine Type Phase Odds Ratio(95% CI) Included Study
Heterogeneity
Test, I-Squared
Cough Adenovirus-based 1/2/3 1.76 (1.20–2.58) 3 0
Fever
Adenovirus-based 1/2/3 1.73 (0.57–5.66) 3 90.5
Inactivated 1/2/3 0.27 (0.09–0.76) 5 0
Pro-Subunit 1/2/3 1.17 (0.73–1.86) 4 0
mRNA-based 1/2/3 36.90 (12.34–105.21) 3 43.31
Headache
mRNA-based
3 4.63 (4.4–4.86) 1 0
2 2.32 (1.28–4.19) 4 69.20
1/2 5.13 (2.32–11.31) 5 63.02
Adenovirus-based
2 2.54 (1.65–3.91) 2 0
1/2 3.01 (2.35–3.87) 1 0
3 0.58 (0.49–0.68) 1 0
Inactivated 2 0.18 (0.02–1.14) 2 0
Pro-Subunit
2 1.25 (0.33–4.7) 2 0
1/2 1.99 (1.21–3.26) 14 0
Fatigue
Adenovirus-based 1/2 2.72 (2.2–3.37) 3 0
Inactivated 1/2 0.39 (0.18–0.82) 7 0
Pro-Subunit 1/2 2.7 (1.01–7.16) 4 37.2
mRNA-based
1/2 5.0 (3.42–7.33) 24 48.23
2–3 4.87 (4.65–5.09) 1 0
3 6.16 (5.86–6.48) 1 0
Induration
Adenovirus-based 1/2 0.16 (0.05–0.49) 2 46.44
Inactivated 1/2 0.18 (0.06–0.58) 4 0
Pro-Subunit 1/2 2.62 (1.23–5.58) 2 0
mRNA-based 1/2 17.5 (1.96–155.58) 1 0
Vomiting
Adenovirus-based 1/2 2.75 (1.99–3.82) 3 0
Inactivated 1/2 0.32 (0.02–5.38) 1 0
mRNA-based
1/2 8.71 (4.38–17.34) 8 0
2–3 4.87 (4.65–5.09) 1 0
3 6.16 (5.86–6.48) 1 0
Diarrhea
Adenovirus-based 1/2 2.51 (1.12–5.63) 2 0
Inactivated 1/2 0.60 (0.13–2.83) 3 0
mRNA-based 1/2 0.54 (0.27–1.10) 5 0
Myalgia
Adenovirus-based 1/2 4.59 (3.58–5.89) 3 0
Inactivated 1/2 1.43 (0.25–8.08) 2 0
Pro-Subunit 2.92 (0.57–8.75) 8 53.30
mRNA-based
1/2 10.71 (6.51–17.60) 10 33.74
2/3 7.0 (6.57–7.47) 1 0
3 1.43 (0.25–8.08) 1 0
Arthralgia
Adenovirus-based 2/3 4.06 (2.99–5.57) 3 0
Pro-Subunit 2/3 1.34 (0.47–3.83) 4 4.833
mRNA-based 2/3 9.67 (1.27–76.90) 3 67.97
Chills
Adenovirus-based 2/3 10.61 (7.60–14.83) 1 0
mRNA-based 2/3 13.11 (7.19–23.89) 8 3.82
Pruritus
Adenovirus-based 2/3 0.54 (0.23–1.25) 2 0
mRNA-based 2/3 17.50 (1.98–155.58) 1 0
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Serious Adverse Side Effects of COVID-19 Vaccines
Only three studies reported anaphylactic shock as an adverse effect of COVID-19
vaccines—(1) 1 out of 84 vaccine cases for the inactivated vaccine [30]; (2) 1 case out of 2063
vaccinated for the adenovirus-based vaccine [38], (3) 1 case out of 15,181 in the vaccine
group, and 1 case out of 15,170 in the placebo group, for the mRNA-based vaccine [40]. A
total of 37 blot clots, including 22 pulmonary embolus cases (PE) and 5 deep vein throm-
bosis (DVT), have been reported for the Oxford-AstraZeneca vaccine among 17 million
people in the EU and Britain [43]; see discussion for recent contributions. The number of
clotting events is not greater than what is seen in the general population, with no indication
that there is a causal effect.
3.5. Side Effects of COVID-19 Vaccines Based on Different Adjuvants
The sub-group analysis was assessed to estimate the potential side effects of COVID-19
vaccines based on the different types of administrated adjuvants. Interestingly, in all cases,
potassium aluminum sulfate (alum) had the smallest number of systemic and local side
effects compared to other adjuvants or vaccines without adjuvant, except injection site
redness, of which vaccines without adjuvant had higher rates of site redness (Figure 4). Ac-
cordingly, vaccines with alum adjuvant had lower systemic side effects of fatigue OR 0.392
(95% 0.18–0.82), vomiting 0.325 (95% 0.02–5.30), fever 0.85 (95% 0.51–1.43), myalgia 1.43
(95% 0.25–8.0), diarrhea 0.608 (95% 0.13–2.87), and injection site pain 2.40 (95% 1.51–3.83)
between different adjuvants and vaccines with no adjuvant (Table 5). The vaccine with
no adjuvant was associated with higher redness OR 0.923 (95% 0.23–3.6). Itch OR 13.20
(95% 3.23–53.90) and swelling OR of 3.83 (95% 1.52–9.64) was only reported for vaccines
with alum adjuvant. For more detailed information see Figures S22–S30.
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Table 5. Side effects of COVID-19 vaccines based on different adjuvant types.







Alum 2/3 0.392 (0.18–0.82) 7 0
Matrix-M1 2/3 3.70 (1.36–10.02) 3 24.81
No adjuvant 2/3 4.43 (2.62–7.49) 6 54.08
Vomiting Alum 2/3 0.325 (0.02–5.30) 1 0
No adjuvant 2/3 3.46 (1.45–8.26) 7 0
Fever
Alum 2/3 0.85 (0.51–1.43) 9 20.78
No adjuvant 2/3 2.96 (1.22–7.17) 2 68.19
Myalgia
Alum 2/3 1.43 (0.25–8.0) 2 0
AS03 2/3 14.331 (3.39–60.56) 3 0
CpG/Alum 2/3 2.42 (0.13–44.50) 1 0
Matrix-M1 2/3 1.57 (0.26–9.4) 3 67.96
No adjuvant 2/3 9.66 (3.97–23.47) 8 49.99
Diarrhea
Alum 2/3 0.608 (0.13–2.87) 3 0
No adjuvant 2/3 0.89 (0.40–1.97) 6 50.47
Local
Injection site pain Alum 2/3 2.40 (1.51–3.83) 22 44.55
No adjuvant 2/3 25.61 (13.31–49.30) 7 36.60
Itch Alum 2/3 13.20 (3.23–53.90) 7 40.58
Swelling Alum 2/3 3.83 (1.52–9.64) 7 37.52
Redness
Alum 2/3 7.29 (3.7–14.39) 6 0
No adjuvant 2/3 0.923 (0.23–3.6) 2 0
Alum = aluminum, CpG = cytosine-guanine oligodeoxynucleotide, AS03 = squalene-based immunologic adjuvant.
4. Discussion
The purpose of vaccination is to protect individuals from infection and transmission.
Although the emergency use authorization for some of the COVID-19 vaccines has been
approved by the Food and Drug Administration in the US and the Department of Health
and Human Services of each country, the vaccines’ efficacy and side effects have not yet
been comprehensively discussed, although popular media and politicians have made many
unsubstantiated claims. Therefore, in the current meta-analysis, we provide systematic
and comprehensive data regarding the vaccines’ safety, efficacy, and immunogenicity
against SARS-CoV-2. Here, we mainly focused on available RCTs publications on the safety,
efficacy, and immunogenicity of COVID-19 vaccines.
The present study was carefully surveyed for the general and specific target antigen
efficacy of each vaccine group. Our analysis showed that variation in the efficacy of
vaccines after the first doses are remarkable in comparison with the efficacies after the
second doses. Therefore, enrollment of the second dose should produce a more reliable
outcome and efficacy compared to a single dose. In total, mRNA-based COVID-19 vaccines
had 94.6% efficacy. The RNA-based vaccine elicited high levels of NAbs after one month of
the first (70%) and second (99.5%) doses. Unfortunately, data for the RNA-based vaccines
against RBD antigen were not available after the first dose. Protection against variants has
been shown with the mRNA-based vaccine against the United Kingdom (B.1.1.7, also called
20I/501Y.V1) variant [44,45], but they may be less effective against the variant first detected
in South Africa (B.1.351, known as 20H/501Y.V2) [46]. A week after the second dose of
mRNA-based vaccine, induction of neutralizing antibody titers in the serum sample was 6-
fold lower for participants bearing B.1.351 variant compared to original Wuhan-Hu-1 spike
protein [47]. The B.1.351 variant carries two substitutions within the S-protein, which can
escape three classes of therapeutically relevant antibodies. These data indicate reinfection
with antigenically distinct variants and mitigates the full efficacy of spike-based COVID-19
vaccines [48].
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From our summary analysis, the total efficacy of the adenovirus-vectored COVID-19
vaccines was 80.2%. The highest efficacy after a single dose is reported with the adenovirus-
vectored COVID-19 vaccines, with very low variation and CI against RBD at 3 weeks
(96.7%) and 4 weeks (96.6%) after vaccination compared to placebo controls. Some of the
adenovirus-vectored COVID-19 vaccines, such as Johnson & Johnson, need just one dose,
with the efficacy against RBD being a possible reason. However, based on the rollout
timeline, long-term (more than four weeks) efficacy of adenovirus-vectored COVID-19
vaccines was not reported by any of the RCTs. For the other vaccine types, total efficacy
has not been reported, only the antigen-specific efficacy was reported in these RCTs. The
pro-subunit vaccine had the highest efficacy against spike antigen at 1 month after the first
injection. The efficacy of the VLP vaccines was lower than other COVID-19 vaccines and
reported only against RBD after the first (23.8%) and second dose (78.7%). All reports for
VLP vaccines are from RCT phase I trials, and the lower efficacy of these vaccines may be
the most probable reason.
Any vaccine is expected to cause temporary side effects caused by activation of an
immune response and injection site tissue trauma. Uptake of vaccines is related to perceived
and real adverse side effects, both short-term and long-term. In this study, adjusted pooled
odds ratios between vaccine and placebo groups indicated that RNA-based vaccines had
higher rates of side effects in reactogenicity, including site pain, swelling, redness, fever,
headache, fatigue, induration, vomiting, myalgia, chills, and pruritus (Table 2). No sign of
cough or itch was found in RNA-based vaccines, and lower rates of diarrhea and arthralgia
were observed for this vaccine. By avoiding negativity bias, this might provide strong
evidence of RNA-based vaccines’ effectiveness, by eliciting a more robust immune response
than other vaccine groups. Additionally, the rate of serious adverse side effects such as
anaphylactic shock, an allergic reaction, was not remarkable with this vaccine, with only
one case reported in both the vaccine and placebo groups [40].
In the context of side effects, the adenovirus-vectored vaccines are associated with
increased diarrhea and arthralgia in comparison with other vaccines, see Table 2. A recent
systematic review and meta-analysis by Yuan et al. [49] showed no significant difference in
systemic reactions, with only local side effects, including pain, itching, and redness, being
reported [49]. One case of anaphylactic shock was reported for this vaccine [38].
Several pulmonary emboli (PE) and deep vein thrombosis (DVT) cases have been re-
ported as rare events for the Oxford-AstraZeneca vaccine, causing a temporary suspension
of this vaccine’s use in many countries and age-specific rollout in others. However, to
date, the data are too weak and anecdotal to provide clear evidence of cause and effect [50].
Similarly, the Johnson & Johnson vaccine was also temporarily suspended in April 2021
by the FDA, as several people developed rare blood-related problems of thrombosis with
thrombocytopenia syndrome leading to cerebral venous sinus thrombosis (CVST) [51].
A DVT has also been reported shortly after the second dose of an mRNA-based vaccine
as well [52]. Anaphylaxis as an acute allergic reaction has also been reported as a rare
event for some vaccines, such as mRNA COVID-19 vaccines [53] and adenovector vaccines
against COVID-19 [54]. Overall, these severe life-threatening adverse events are occurring
rarely, thus supporting the ongoing rollout of global vaccination programs.
Data are currently emerging on Vaccine-induced Immune Thrombotic Thrombocy-
topenia (VITT) following vaccination with COVID-19 vaccines [55]. VITT presents with
symptoms of thromboembolism and especially signs of thrombocytopenia, cerebral blood
clots, or abdominal or arterial clots, such as easy bruising, bleeding or new and/or severe
headaches, and pain in the abdomen or a painful, cold numb extremity, particularly with
onset 4 to 28 days after immunization. This is due to thrombosis (blood clots) involving the
cerebral venous sinuses, or CVST (large blood vessels in the brain), and other sites in the
body (including but not limited to the large blood vessels of the abdomen and the veins of
the legs) along with thrombocytopenia, or low blood platelet counts. These events are rare,
but to date have been documented for the mRNA vaccines BNT162b2 (Pfizer-BioNTech)
and mRNA-1273 (Moderna) and the adenoviral vector vaccines ChAdOx1 nCoV-19 vaccine
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(Astra Zeneca) and Ad26. COV2-S vaccine (Janssen; Johnson & Johnson). Given the very
recent emergence, our meta study does not include an analysis of VITT.
Co-administration of vaccine with adjuvants is being used in VLP subunit vaccines
and certain inactivated vaccines [55]. Adjuvants have an essential role owning to inducing
specific immune responses, IgG1, and NAbs titers. It also considers potential dose-sparing
of CoV vaccine [56]. Multiple adjuvants, such as alum salts, emulsions, and TLR agonists
have been formulated for SARS-CoV, SARS-CoV-2, and MERS-CoV [55]. The potential
side effects of COVID-19 vaccines based on the different types of adjuvants investigated
showed that alum-adjuvanted CoV vaccines had the lowest systemic side effects among
other adjuvants or non-adjuvant in Table 3. The non-adjuvanted vaccines revealed im-
munopathologic reactions including high fatigue, vomiting, fever, myalgia, and diarrhea
and redness, while alum-adjuvanted CoV vaccines showed itch and swelling. Overall, the
metadata obtained in this study demonstrated that the alum-adjuvanted CoV vaccines
had the smallest number of issues compared with other adjuvants and the non-adjuvant
formulations.
The limitations of this study are: 1. The overall effectiveness and antigen-specific
efficacy of some vaccines have not been reported after the first or second dose. 2. Some
trials had considerable bias by not including a sufficient number of samples or a broad
enough geographical, economic, and age diversity. 3. Timing of vaccine trials in relation
to overall prevalence through the COVID-19 pandemic impacts direct comparison. 4. The
IgG and IgM antibodies in serum levels had a wide range of variation across the different
vaccines after the first or second dose, thus, these data were not included in the meta-
analysis. 5. The lack of data on specific categories of patients such as pregnant patients
and lifestyles. 6. All RCTs followed up the vaccine and placebo groups one month after
both first and second doses, therefore, all reports are related to short-term impacts of
the vaccine. 7. For the prevention of database bias, we searched various databases and
websites for finding all relevant and gray publications and a proper test for publication
bias using Egger’s regression test conducted. We did not find remarkable publication bias
in this study by Egger’s regression test. However, publication bias and heterogeneity for
some of the pooled results, as well as all the above limitations, must be considered when
interpreting the outcomes.
5. Conclusions
The adenovirus-vectored and mRNA-based vaccines for COVID-19 showed the high-
est efficacy after first and second doses, respectively. The mRNA-based vaccines had higher
side effects. Only a rare few recipients have experienced extreme adverse effects and
all stimulated robust immune responses. All RCTs followed up the vaccine and placebo
groups after one month after both first and second doses, therefore, all reports are related
to short-term impacts. Due to the timeline, all the vaccines are missing longer-term assess-
ments. This meta-analysis allows us to incorporate relevant new evidence for summarizing
and analyzing the clinical features of current vaccines for COVID-19 in phase I, II, and
III RCTs. The results support the overall efficacy and safety of all available COVID-19
vaccines, providing clear data-driven evidence to support the ongoing global public health
effort to vaccinate the entire population.
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